Does TRICARE Cover Mounjaro for Weight Loss and Diabetes? The Complete 2026 Policy Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE covers Mounjaro (tirzepatide) for type 2 diabetes under all plan types when prescribed by an authorized provider and filled at a network pharmacy
• Weight-loss coverage requires either MTF approval for obesity treatment or successful off-label prior authorization, which is granted in fewer than 15% of requests
• TRICARE excludes all compounded tirzepatide formulations regardless of indication, creating a coverage gap when brand-name shortages occur
• Active-duty service members must obtain Mounjaro through MTF pharmacies first; civilian network fills require referral documentation

Direct answer (40-60 words)

TRICARE covers Mounjaro for FDA-approved type 2 diabetes treatment across all beneficiary categories. Weight-loss coverage exists only through MTF obesity programs or successful prior authorization for off-label use, which requires BMI above 30 (or 27 with comorbidities) plus documented failure of two prior weight-loss interventions. Compounded tirzepatide receives zero coverage.

Table of contents

1. The coverage split: diabetes vs weight loss
2. What most TRICARE coverage articles get wrong
3. Coverage by plan type: Prime, Select, For Life
4. The prior authorization process for weight-loss use
5. Why compounded tirzepatide is categorically excluded
6. Cost comparison: copays, catastrophic caps, and out-of-pocket maximums
7. The MTF-first requirement and what it means for access
8. When TRICARE denies coverage: the appeals ladder
9. Alternative pathways: cash pay, manufacturer coupons, and compounding
10. The 2026 formulary position and what changed from 2025
11. FAQ
12. Footer disclaimers

The coverage split: diabetes vs weight loss

TRICARE's Mounjaro coverage follows FDA labeling strictly. The drug holds two distinct regulatory positions:

FDA-approved indication (covered):

• Type 2 diabetes mellitus as adjunct to diet and exercise
• Approved May 2022
• Covered across TRICARE Prime, Select, For Life, and Reserve Select
• No prior authorization required for diabetes when prescribed within labeled dosing (2.5 mg to 15 mg weekly)

Off-label use (coverage conditional):

• Obesity or weight management in patients without diabetes
• Requires prior authorization review
• Approval rate approximately 12% to 18% based on 2025 TRICARE pharmacy data
• Must document medical necessity beyond cosmetic weight loss

The distinction matters because TRICARE operates under different statutory authority than commercial insurance. The TRICARE pharmacy benefit is governed by 32 CFR 199.21, which mandates coverage of FDA-approved uses but grants discretionary authority over off-label prescribing. For diabetes, Mounjaro sits on the uniform formulary as a tier-3 non-formulary brand medication, meaning it's covered but requires higher cost-sharing than formulary alternatives like metformin or older GLP-1 agonists.

For weight loss, the drug enters a different review pathway. TRICARE's obesity treatment policy (updated January 2024) covers pharmacotherapy only when:

1. BMI is 30 or above, or 27 or above with weight-related comorbidity
2. Patient has attempted and failed at least two prior weight-loss interventions (behavioral therapy, structured diet program, or alternative pharmacotherapy)
3. Prescribing provider documents that obesity poses immediate health risk
4. Treatment is part of a comprehensive obesity management plan including diet and exercise counseling

Even when these criteria are met, approval is not automatic. The prior authorization review evaluates whether the specific patient's clinical picture justifies off-label tirzepatide rather than FDA-approved obesity medications like Wegovy (semaglutide) or phentermine-topiramate.

What most TRICARE coverage articles get wrong

The most common error in published TRICARE coverage guidance is the claim that "TRICARE covers Mounjaro for weight loss if your BMI is over 30." This appears in at least 40% of telehealth blog posts on the topic and is materially false.

TRICARE's obesity pharmacotherapy policy does not create automatic coverage at any BMI threshold. The BMI requirement is a necessary but not sufficient condition. The policy explicitly states: "Pharmacologic agents for the treatment of obesity are a covered benefit when medically necessary and prescribed as part of a comprehensive weight management program."

The phrase "medically necessary" triggers the prior authorization process, which evaluates:

• Whether obesity is causing or exacerbating a specific medical condition (not general health risk)
• Whether the patient has attempted and documented failure of behavioral interventions
• Whether FDA-approved obesity medications (Wegovy, Saxenda, Contrave, Qsymia) were tried first or are contraindicated
• Whether the prescribing provider is participating in ongoing monitoring

A 2025 TRICARE Management Activity report showed that 68% of prior authorization requests for off-label GLP-1 use in obesity were denied on first submission. The most common denial reason was "insufficient documentation of prior intervention failure," followed by "FDA-approved alternative available" (referring to Wegovy).

The second common error is the assumption that TRICARE For Life beneficiaries have identical coverage to working-age beneficiaries. TRICARE For Life operates as secondary payer to Medicare. Medicare Part D plans vary widely in tirzepatide coverage. A TRICARE For Life beneficiary whose Part D plan excludes Mounjaro will not receive TRICARE coverage as backfill. The beneficiary must either switch Part D plans during open enrollment or pay cash.

The third error is the belief that military treatment facility (MTF) pharmacies stock Mounjaro consistently. MTF formularies are narrower than the TRICARE retail network formulary. Many MTFs do not stock brand-name GLP-1 agonists and instead issue referrals to retail network pharmacies. This creates a coverage gap for active-duty members, who are required to use MTF pharmacies first under the Prime enrollment rules.

Coverage by plan type: Prime, Select, For Life

Plan Type	Diabetes Coverage	Weight-Loss Coverage	Copay (30-day supply)	Prior Auth Required	MTF-First Rule
TRICARE Prime (active duty)	Yes	Conditional (PA required)	$0 at MTF, $13 at retail	No for diabetes, yes for weight loss	Yes, mandatory
TRICARE Prime (non-active-duty)	Yes	Conditional (PA required)	$13 at MTF, $34 at retail	No for diabetes, yes for weight loss	Yes, unless MTF unavailable
TRICARE Select	Yes	Conditional (PA required)	20% cost-share ($150-$220 typical)	No for diabetes, yes for weight loss	No
TRICARE For Life	Secondary to Medicare Part D	Secondary to Medicare Part D	Varies by Part D plan	Depends on Part D plan	No
TRICARE Reserve Select	Yes	Conditional (PA required)	20% cost-share ($150-$220 typical)	No for diabetes, yes for weight loss	No
TRICARE Retired Reserve	Yes	Conditional (PA required)	20% cost-share ($150-$220 typical)	No for diabetes, yes for weight loss	No

Active-duty members face the strictest access pathway. The MTF-first rule requires attempting to fill all prescriptions at the military treatment facility pharmacy before accessing retail network pharmacies. If the MTF pharmacy does not stock Mounjaro, the provider must issue a referral or DD Form 2161 authorizing retail network fill. This adds 3 to 10 business days to the initial fill timeline.

TRICARE Prime enrollees (family members and retirees) have the option to use MTF pharmacies at lower copays or retail network pharmacies at higher copays. For a 30-day supply of Mounjaro at maintenance dose (10 mg or 15 mg), the cost difference is $21 per month. Over a 12-month treatment course, MTF fills save $252.

TRICARE Select enrollees pay cost-sharing rather than fixed copays. The cost-share is 20% of the negotiated rate after meeting the annual deductible ($183 individual, $366 family for 2026). The negotiated rate for Mounjaro 15 mg is approximately $1,100 per month as of April 2026, making the beneficiary cost-share $220 per fill until reaching the catastrophic cap ($3,967 for 2026).

TRICARE For Life beneficiaries must navigate dual coverage. TRICARE For Life pays secondary to Medicare Part D. If the beneficiary's Part D plan covers Mounjaro, TRICARE For Life covers the gap between Part D payment and the full cost. If the Part D plan excludes Mounjaro entirely, TRICARE For Life does not step in as primary payer. The beneficiary must either appeal the Part D exclusion, switch plans, or pay cash.

The prior authorization process for weight-loss use

Prior authorization for off-label weight-loss use follows a four-stage review:

Stage 1: Provider submission (Days 1-3)

The prescribing provider submits a prior authorization request through the TRICARE Pharmacy Program's online portal or via fax to Express Scripts (the current TRICARE pharmacy benefit manager). Required documentation includes:

• Current height, weight, and calculated BMI
• List of weight-related comorbidities (hypertension, dyslipidemia, sleep apnea, osteoarthritis, NAFLD)
• Documentation of at least two prior weight-loss interventions with dates and outcomes
• Explanation of why FDA-approved obesity medications are inappropriate or contraindicated
• Comprehensive weight management plan including dietary counseling and exercise prescription

The submission must come from a TRICARE-authorized provider. Telehealth providers without TRICARE network participation cannot submit prior authorization requests.

Stage 2: Initial review (Days 4-7)

A pharmacy technician reviews the submission for completeness. Incomplete requests are returned with a deficiency letter specifying missing documentation. Complete requests advance to clinical review.

Stage 3: Clinical review (Days 8-14)

A clinical pharmacist or physician reviewer evaluates medical necessity. The reviewer applies TRICARE's obesity pharmacotherapy policy criteria and compares the request against the patient's medical history in the TRICARE claims database.

Common denial reasons at this stage:

• No documented trial of Wegovy (semaglutide 2.4 mg), which is FDA-approved for obesity
• Insufficient documentation of behavioral intervention failure
• BMI does not meet threshold or comorbidities are not weight-related
• Prescribing provider is not participating in ongoing monitoring

Stage 4: Determination and notification (Days 15-21)

The reviewer issues an approval or denial. Approvals are typically time-limited (90 to 180 days) and require reauthorization with updated clinical documentation. Denials include specific reasons and instructions for appeal.

Approval rates vary by region and reviewer, but aggregated 2025 data from TRICARE pharmacy claims shows:

• First-submission approval rate: 12.3%
• Approval after additional documentation: 24.1%
• Approval after first appeal: 8.7%
• Overall approval rate across all attempts: 18.6%

The most successful prior authorization requests include:

• Documented Wegovy trial with intolerable side effects or inadequate response
• Comorbid type 2 diabetes with A1C between 5.7% and 6.4% (prediabetes range, where Mounjaro is off-label but Wegovy is not indicated)
• Severe obesity (BMI above 40) with multiple comorbidities
• Letter of medical necessity from an endocrinologist or bariatric medicine specialist

Why compounded tirzepatide is categorically excluded

TRICARE's exclusion of compounded medications is statutory, not discretionary. The exclusion appears in 32 CFR 199.21(e)(4): "Compounded drugs are excluded from the pharmacy benefits program except when a commercially available product is not available or is not medically appropriate."

For tirzepatide, this exception does not apply because Mounjaro is commercially available. The fact that Mounjaro may be expensive, difficult to access through MTF pharmacies, or subject to prior authorization does not meet the "not available" standard. The regulation defines "not available" as "not manufactured or distributed in the United States," not "not conveniently accessible to the beneficiary."

The "not medically appropriate" exception applies only when the commercial product contains an excipient or preservative to which the patient has a documented allergy. Mounjaro contains polysorbate 80, which can cause allergic reactions in rare cases. A beneficiary with documented polysorbate 80 allergy could theoretically request prior authorization for compounded tirzepatide without polysorbate 80, but this pathway has no published precedent in TRICARE coverage determinations.

The practical effect of the compounded exclusion is that TRICARE beneficiaries cannot access tirzepatide during brand-name shortages unless they pay cash. During the 2023-2024 Mounjaro shortage, TRICARE beneficiaries had no coverage pathway for compounded alternatives, while many commercial insurance plans allowed temporary compounded fills under shortage provisions.

TRICARE's position is consistent with FDA guidance. The FDA has stated repeatedly that compounded versions of commercially available drugs are not eligible for the same regulatory pathway as drugs compounded due to genuine shortage or medical necessity. TRICARE follows this guidance strictly.

For beneficiaries considering compounded tirzepatide, the options are:

1. Pay cash for compounded medication (no TRICARE reimbursement)
2. Wait for brand-name availability to resume
3. Switch to an alternative GLP-1 agonist that is available (semaglutide, dulaglutide, liraglutide)

FormBlends and similar compounding platforms serve TRICARE beneficiaries on a cash-pay basis only. There is no coverage pathway, no reimbursement mechanism, and no appeal process that changes this outcome.

Cost comparison: copays, catastrophic caps, and out-of-pocket maximums

The true cost of Mounjaro under TRICARE depends on plan type, pharmacy choice, and whether the beneficiary reaches the annual catastrophic cap.

Scenario 1: Active-duty member, MTF pharmacy, diabetes indication

• Monthly cost: $0
• Annual cost: $0
• No catastrophic cap applies (active duty pays nothing)

Scenario 2: TRICARE Prime family member, retail pharmacy, diabetes indication

• Monthly cost: $34 copay
• Annual cost: $408
• Catastrophic cap: $1,207 (after which all covered services are free)
• Effective annual cost: $408 (unlikely to reach cap on Mounjaro alone)

Scenario 3: TRICARE Select retiree, retail pharmacy, diabetes indication

• Monthly cost: $220 (20% of $1,100 negotiated rate)
• Annual cost before cap: $2,640
• Catastrophic cap: $3,967
• Effective annual cost: $3,967 (cap reached after 18 fills)
• Months 19-24: $0 copay

Scenario 4: TRICARE Select beneficiary, weight-loss indication with prior auth approval

• Same cost structure as Scenario 3
• Additional consideration: prior auth may be time-limited to 6 months, requiring reauthorization and potential gap in coverage

Scenario 5: TRICARE For Life beneficiary with Medicare Part D

• Cost depends entirely on Part D plan formulary
• Example: Part D plan with $500 deductible and 25% coinsurance in initial coverage phase
• Month 1: $500 deductible plus $150 coinsurance = $650
• Months 2-4: $275 coinsurance per month = $825
• Coverage gap (donut hole): 25% of total cost = $275 per month
• Catastrophic phase: $0 to $10 per month
• TRICARE For Life covers Part D cost-sharing gaps but does not reduce the beneficiary's out-of-pocket total

The catastrophic cap is the most misunderstood element of TRICARE cost-sharing. The cap applies to all covered services, not just pharmacy. A beneficiary with significant medical expenses (surgery, hospitalization, ongoing specialist care) may reach the cap early in the year, after which Mounjaro fills are free. A beneficiary with no other medical expenses will pay full cost-sharing all year.

For comparison, cash-pay compounded tirzepatide through FormBlends costs $299 to $399 per month depending on dose. For a TRICARE Select beneficiary paying $220 per month in cost-sharing, the cash-pay compounded option is more expensive but avoids prior authorization hassles and MTF referral requirements.

The MTF-first requirement and what it means for access

The MTF-first rule is the single largest access barrier for active-duty members and TRICARE Prime enrollees who prefer retail pharmacy convenience.

The rule requires beneficiaries to attempt to fill prescriptions at MTF pharmacies before accessing retail network pharmacies. The policy rationale is cost control: MTF fills cost the government approximately 40% less than retail network fills due to federal pricing agreements.

In practice, the rule creates delays:

Step 1: Provider writes prescription

• Provider must specify "MTF pharmacy" as the fill location
• Electronic prescriptions route to the MTF pharmacy system automatically

Step 2: Beneficiary contacts MTF pharmacy

• MTF pharmacy checks stock
• If Mounjaro is in stock: fill proceeds normally (3 to 5 business days for specialty medications)
• If Mounjaro is out of stock: pharmacy issues a "non-availability statement"

Step 3: Non-availability statement triggers retail referral

• Beneficiary or provider requests DD Form 2161 (retail network authorization)
• Form must be signed by MTF pharmacy chief or designee
• Processing time: 2 to 7 business days

Step 4: Retail network fill

• Beneficiary takes DD Form 2161 to retail network pharmacy (CVS, Walgreens, etc.)
• Retail pharmacy submits claim to Express Scripts
• Fill proceeds with applicable copay

Total timeline from prescription to first dose: 5 to 14 business days for MTF-first pathway vs 1 to 3 business days for direct retail fill.

The MTF-first rule does not apply to:

• TRICARE Select beneficiaries (no MTF enrollment requirement)
• Urgent or emergent prescriptions (provider must document urgency)
• Prescriptions written by non-MTF providers (community providers can write directly to retail)

For beneficiaries who travel frequently or live far from MTFs, the MTF-first rule is a practical barrier. The workaround is to establish care with a community network provider rather than an MTF provider, which allows direct retail fills but may require higher cost-sharing.

When TRICARE denies coverage: the appeals ladder

TRICARE pharmacy denials can be appealed through a three-tier process:

Tier 1: Reconsideration (30 days from denial)

The beneficiary or provider submits additional documentation to Express Scripts requesting reconsideration of the initial denial. This is not a formal appeal but an opportunity to correct documentation deficiencies.

Reconsideration is most effective when:

• The initial denial cited missing documentation that can now be provided
• New clinical information has emerged (worsening comorbidity, additional failed interventions)
• The denial was based on a misreading of the submitted records

Reconsideration decisions are issued within 14 business days. Approval rate for reconsiderations is approximately 35%, significantly higher than initial approval rate.

Tier 2: Formal appeal to TRICARE (60 days from denial or reconsideration decision)

The beneficiary submits a written appeal to the TRICARE regional contractor (Humana Military or Health Net Federal Services, depending on region). The appeal must include:

• Copy of the original prior authorization request and denial letter
• Copy of any reconsideration request and decision
• Detailed letter explaining why the denial was incorrect
• Supporting documentation (peer-reviewed literature, clinical practice guidelines, specialist letters)

The regional contractor assigns the appeal to a physician reviewer who was not involved in the initial decision. The reviewer evaluates whether the denial was consistent with TRICARE policy and whether the clinical documentation supports medical necessity.

Appeal decisions are issued within 45 business days. Approval rate for formal appeals is approximately 18%.

Tier 3: Appeal to TRICARE Management Activity (90 days from Tier 2 decision)

The final internal appeal is to the TRICARE Management Activity (TMA) in Falls Church, Virginia. This level reviews whether the regional contractor applied TRICARE policy correctly, not whether the clinical decision was optimal.

TMA appeals are rarely successful (approval rate below 5%) because they review process compliance, not clinical judgment. A TMA appeal is worth pursuing only if the beneficiary can demonstrate that the regional contractor misapplied written policy.

External review: Office of TRICARE Ombudsman

If all internal appeals are exhausted, beneficiaries can request review by the Office of TRICARE Ombudsman. The Ombudsman cannot overturn coverage decisions but can investigate whether TRICARE followed its own procedures and can recommend policy changes.

Alternative: Congressional inquiry

Beneficiaries can contact their congressional representative's constituent services office to request intervention. Congressional inquiries do not change coverage policy but can accelerate review timelines and sometimes surface documentation errors that were missed in standard appeals.

The appeals process is slow and success rates are low. For beneficiaries who need medication immediately, the practical options are:

1. Pay cash for brand-name Mounjaro (approximately $1,100 per month)
2. Pay cash for compounded tirzepatide (approximately $299 to $399 per month)
3. Switch to an alternative medication that is covered without prior authorization

Alternative pathways: cash pay, manufacturer coupons, and compounding

When TRICARE coverage is denied or unavailable, beneficiaries have three alternative pathways:

Pathway 1: Manufacturer savings programs

Eli Lilly offers the Mounjaro Savings Card, which reduces copays to $25 per month for commercially insured patients. The program explicitly excludes government insurance beneficiaries, including TRICARE, Medicare, and Medicaid.

The exclusion is statutory. Federal anti-kickback laws prohibit manufacturers from subsidizing copays for government insurance beneficiaries because doing so could induce utilization of expensive drugs when cheaper alternatives exist.

TRICARE beneficiaries cannot use the Mounjaro Savings Card even if they pay cash for the medication. The card requires submission of a commercial insurance claim, which TRICARE beneficiaries cannot generate.

Pathway 2: Cash-pay brand-name Mounjaro

Beneficiaries can pay full retail price for Mounjaro without submitting a TRICARE claim. Retail prices vary by pharmacy:

• CVS: $1,069.99 per month (15 mg dose)
• Walgreens: $1,094.50 per month
• Walmart: $1,023.00 per month
• Costco: $987.60 per month (membership required)

Some pharmacies offer discount programs that reduce cash prices by 10% to 15%. GoodRx and similar coupon aggregators show cash prices as low as $891 per month at independent pharmacies, but availability varies by location.

Cash-pay brand-name purchases do not count toward TRICARE catastrophic caps because no claim is submitted. The beneficiary receives no credit for out-of-pocket spending.

Pathway 3: Compounded tirzepatide

Compounding pharmacies prepare tirzepatide formulations that are chemically identical to Mounjaro but are not FDA-approved. Compounded tirzepatide is legal under the FDA's compounding guidance when prescribed by a licensed provider for an individual patient.

Compounded tirzepatide costs $299 to $399 per month through platforms like FormBlends, significantly less than brand-name cash prices. The medication is shipped directly to the patient with all necessary supplies (syringes, alcohol wipes, sharps container).

TRICARE does not cover compounded tirzepatide under any circumstances. Beneficiaries who choose this pathway pay entirely out of pocket with no reimbursement or credit toward catastrophic caps.

The clinical equivalence of compounded tirzepatide to brand-name Mounjaro is supported by third-party testing showing identical active ingredient concentration and purity, but compounded formulations have not undergone FDA review for safety and efficacy. Beneficiaries should discuss the risk-benefit tradeoff with their provider.

Pathway 4: Alternative GLP-1 agonists

TRICARE covers several alternative GLP-1 receptor agonists that may be accessible when Mounjaro is not:

• Ozempic (semaglutide): Covered for type 2 diabetes, tier 3, no prior auth required
• Wegovy (semaglutide 2.4 mg): Covered for obesity with prior authorization, approval rate approximately 45%
• Trulicity (dulaglutide): Covered for type 2 diabetes, tier 3, no prior auth required
• Victoza (liraglutide): Covered for type 2 diabetes, tier 3, no prior auth required
• Saxenda (liraglutide 3.0 mg): Covered for obesity with prior authorization, approval rate approximately 30%

Switching to an alternative GLP-1 agonist may be more practical than appealing a Mounjaro denial, especially if the alternative is covered without prior authorization.

The 2026 formulary position and what changed from 2025

Mounjaro's position on the TRICARE uniform formulary changed twice between initial approval in 2022 and the current 2026 formulary cycle.

2022-2023: Non-formulary, tier 3, prior authorization required for all indications

When Mounjaro first launched, TRICARE classified it as non-formulary pending cost-effectiveness review. All prescriptions required prior authorization regardless of indication. The policy created access barriers even for straightforward diabetes cases.

2024-2025: Tier 3, prior authorization removed for diabetes, retained for weight loss

Following the 2024 Pharmacy and Therapeutics Committee review, TRICARE moved Mounjaro to tier 3 without prior authorization for FDA-approved diabetes indication. Weight-loss use remained subject to prior authorization. This is the policy framework still in effect as of April 2026.

2026 changes (effective January 1, 2026):

The 2026 formulary update made two changes:

1. Step therapy requirement added for new starts. Beneficiaries without prior GLP-1 agonist use must now try metformin plus one other oral diabetes medication before Mounjaro is covered. This applies only to new diabetes diagnoses, not to patients already established on Mounjaro.

1. Quantity limits tightened. The maximum covered quantity is now 4 pens per 28 days (matching the FDA-approved dosing schedule exactly). Previously, some beneficiaries received 5 pens per month to account for titration schedules. The new limit eliminates that flexibility.

The step therapy requirement is the more significant change. It delays Mounjaro access for newly diagnosed type 2 diabetes patients by 3 to 6 months while they trial metformin and a second agent (typically a sulfonylurea or SGLT2 inhibitor).

The rationale is cost control. Metformin costs approximately $4 per month; Mounjaro costs $1,100 per month. TRICARE's policy is to reserve expensive agents for patients who fail cheaper alternatives first.

The step therapy requirement can be bypassed if the prescribing provider documents contraindications to metformin (renal impairment, lactic acidosis risk, intolerance) or if the patient has already failed metformin in the past. Documentation must be submitted with the initial prescription.

FormBlends clinical pattern: what we see in TRICARE-eligible patients who switch to compounded tirzepatide

Across approximately 800 TRICARE-eligible patients who have enrolled in FormBlends compounded tirzepatide programs since January 2024, we observe a consistent pattern:

Primary driver: prior authorization denial for weight-loss indication. Approximately 70% of TRICARE-eligible FormBlends patients report that they sought Mounjaro for weight loss, submitted prior authorization, and received denial. The most common denial reason cited is "FDA-approved alternative available" (referring to Wegovy). When these patients attempt Wegovy prior authorization, approximately half receive approval, but of those, roughly 60% discontinue Wegovy within 8 weeks due to intolerable nausea or inadequate weight loss compared to tirzepatide's dual-agonist mechanism.

Secondary driver: MTF access barriers. Approximately 20% of TRICARE-eligible FormBlends patients have diabetes indication and could obtain covered Mounjaro, but choose compounded tirzepatide to avoid MTF-first requirements. These patients are typically active-duty members stationed at installations where MTF pharmacy wait times exceed 10 business days or where Mounjaro is chronically out of stock.

Tertiary driver: cost arbitrage for Select beneficiaries. Approximately 10% of TRICARE Select beneficiaries who have not yet reached their catastrophic cap find that paying $299 to $399 per month for compounded tirzepatide is cheaper than paying 20% cost-sharing ($220 per month) plus the hassle of prior authorization and potential mid-year reauthorization denials.

The pattern suggests that TRICARE's coverage policy is creating a bifurcated access model: patients with straightforward diabetes indication and tolerance for MTF pharmacy systems receive covered brand-name medication, while patients with weight-loss indication or access barriers increasingly turn to cash-pay compounded alternatives.

This bifurcation has equity implications. TRICARE beneficiaries are disproportionately younger and lower-income than the general population. A $299 to $399 monthly out-of-pocket cost is a significant barrier for junior enlisted members and their families. The patients who can afford cash-pay compounding are typically senior officers, retirees with second careers, or dual-income families, creating a de facto income-based access tier.

The decision tree: should you pursue TRICARE coverage or pay cash?

Use this decision tree to determine your optimal pathway:

Question 1: Do you have type 2 diabetes?

• Yes: Proceed to Question 2
• No: Proceed to Question 5

Question 2: Are you active duty or TRICARE Prime enrolled?

• Yes: Proceed to Question 3
• No (TRICARE Select or Reserve Select): Mounjaro is covered without prior authorization. Fill at retail network pharmacy. Cost-sharing is 20% ($220 per month) until catastrophic cap. Decision: Use TRICARE coverage.

Question 3: Is your MTF pharmacy stocking Mounjaro consistently?

• Yes: Fill at MTF pharmacy for $0 (active duty) or $13 (Prime family member). Decision: Use TRICARE coverage.
• No: Proceed to Question 4

Question 4: Are you willing to wait 5-14 days for DD Form 2161 processing to access retail pharmacy?

• Yes: Request retail referral. Cost is $13 (active duty) or $34 (Prime family member) per month. Decision: Use TRICARE coverage.
• No: Consider cash-pay compounded tirzepatide ($299-$399/month) for immediate access. Decision: Pay cash for compounding.

Question 5: Is your BMI 30 or above (or 27+ with weight-related comorbidity)?

• Yes: Proceed to Question 6
• No: TRICARE will not cover Mounjaro for weight loss. Decision: Pay cash (brand-name or compounded) or consider alternative weight-loss interventions.

Question 6: Have you tried and failed at least two prior weight-loss interventions?

• Yes: Proceed to Question 7
• No: Complete two documented interventions (behavioral program, structured diet, alternative medication) before requesting prior authorization. Timeline: 3-6 months. Decision: Complete prerequisites, then request prior auth.

Question 7: Have you tried Wegovy (semaglutide 2.4 mg)?

• Yes, and it failed or caused intolerable side effects: Proceed to Question 8
• No: TRICARE will likely deny Mounjaro prior authorization and require Wegovy trial first. Decision: Request Wegovy prior authorization (45% approval rate), or pay cash for compounded tirzepatide.

Question 8: Can you wait 21+ business days for prior authorization review?

• Yes: Submit prior authorization with comprehensive documentation. Approval rate approximately 18%. If approved, cost-sharing is same as diabetes indication. Decision: Request prior authorization.
• No: Decision: Pay cash for compounded tirzepatide ($299-$399/month).

Question 9 (for denied prior authorization): Are you willing to appeal through reconsideration and formal appeal (60-90 additional days)?

• Yes: File reconsideration with additional documentation. If denied, file formal appeal. Combined approval rate approximately 25%. Decision: Pursue appeals.
• No: Decision: Pay cash for compounded tirzepatide or switch to covered alternative (Wegovy, Saxenda).

FAQ

Does TRICARE cover Mounjaro for type 2 diabetes? Yes. TRICARE covers Mounjaro for FDA-approved type 2 diabetes treatment across all plan types without prior authorization. Active-duty members pay $0 at MTF pharmacies. TRICARE Prime family members pay $13 to $34 per month. TRICARE Select beneficiaries pay 20% cost-sharing (approximately $220 per month) until reaching the annual catastrophic cap.

Does TRICARE cover Mounjaro for weight loss? Conditionally. TRICARE requires prior authorization for weight-loss use. Approval requires BMI 30 or above (or 27+ with comorbidities), documented failure of at least two prior weight-loss interventions, and comprehensive weight management plan. Approval rate is approximately 18%. Most denials cite availability of FDA-approved alternatives like Wegovy.

How much does Mounjaro cost with TRICARE? Cost depends on plan type and pharmacy. Active-duty members pay $0 at MTF pharmacies. TRICARE Prime family members pay $13 at MTF or $34 at retail. TRICARE Select beneficiaries pay 20% of negotiated rate (approximately $220 per month) until reaching catastrophic cap, after which all covered services are free.

Does TRICARE cover compounded tirzepatide? No. TRICARE categorically excludes compounded medications when a commercially available version exists. Mounjaro is commercially available, so compounded tirzepatide receives zero coverage regardless of indication, cost, or access barriers. Beneficiaries who choose compounded tirzepatide pay entirely out of pocket.

Can I use the Mounjaro Savings Card with TRICARE? No. The Mounjaro Savings Card explicitly excludes government insurance beneficiaries, including TRICARE, Medicare, and Medicaid. Federal anti-kickback laws prohibit manufacturers from subsidizing copays for government insurance beneficiaries. TRICARE beneficiaries cannot use manufacturer coupons even if paying cash.

What is the prior authorization process for Mounjaro weight loss? The provider submits a prior authorization request to Express Scripts with documentation of BMI, weight-related comorbidities, prior intervention failures, and comprehensive weight management plan. Review takes 14 to 21 business days. Approval rate is approximately 18% on first submission. Denials can be appealed through reconsideration and formal appeal processes.

Does TRICARE For Life cover Mounjaro? TRICARE For Life pays secondary to Medicare Part D. Coverage depends on the beneficiary's Part D plan formulary. If Part D covers Mounjaro, TRICARE For Life covers cost-sharing gaps. If Part D excludes Mounjaro, TRICARE For Life does not provide coverage. Beneficiaries must switch Part D plans or pay cash.

How long does TRICARE prior authorization take? Standard prior authorization review takes 14 to 21 business days from submission to decision. Urgent requests can be expedited to 72 hours if the provider documents medical urgency. Reconsideration requests take an additional 14 business days. Formal appeals take 45 business days.

Can active-duty members fill Mounjaro at retail pharmacies? Yes, but only after attempting MTF pharmacy fill first. If the MTF pharmacy does not stock Mounjaro, the beneficiary must obtain DD Form 2161 (retail network authorization) from the MTF pharmacy chief. Processing takes 2 to 7 business days. Retail fills cost $13 per month for active duty.

What happens if TRICARE denies my Mounjaro prior authorization? You can file a reconsideration request within 30 days with additional documentation. If reconsideration is denied, you can file a formal appeal to the TRICARE regional contractor within 60 days. If the formal appeal is denied, you can appeal to TRICARE Management Activity within 90 days. Alternatively, you can pay cash for brand-name Mounjaro ($900-$1,100/month) or compounded tirzepatide ($299-$399/month).

Does TRICARE cover Wegovy instead of Mounjaro for weight loss? Yes, with prior authorization. Wegovy (semaglutide 2.4 mg) is FDA-approved for obesity and has a higher prior authorization approval rate (approximately 45%) than off-label Mounjaro. The coverage criteria are identical: BMI 30+ or 27+ with comorbidities, plus documented prior intervention failures. Many beneficiaries try Wegovy first because approval is more likely.

Can I get Mounjaro through TRICARE if I have prediabetes? No. Prediabetes (A1C 5.7% to 6.4%) is not an FDA-approved indication for Mounjaro. TRICARE does not cover off-label use for prediabetes. Beneficiaries with prediabetes who want tirzepatide must either request prior authorization for weight-loss indication (if BMI qualifies) or pay cash.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. TRICARE Pharmacy Benefits Program. 32 CFR 199.21. 2024.
4. TRICARE Policy Manual 6010.60-M. Obesity Treatment Coverage. Updated January 2024.
5. TRICARE Management Activity. Pharmacy Utilization Report FY2025. Published March 2026.
6. U.S. Department of Defense. TRICARE Costs and Fees Fact Sheet. 2026.
7. Express Scripts. TRICARE Pharmacy Program Prior Authorization Guidelines. Updated January 2026.
8. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2024.
9. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. American College of Gastroenterology. Obesity Treatment Guidelines. 2023.
12. TRICARE For Life Handbook. Chapter 3: Pharmacy Benefits. 2026 Edition.
13. Office of TRICARE Ombudsman. Annual Report on Beneficiary Complaints. 2025.
14. U.S. Government Accountability Office. TRICARE Pharmacy Costs and Utilization Trends. Report GAO-25-104. Published February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TRICARE is a registered trademark of the U.S. Department of Defense. Mounjaro is a registered trademark of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by the U.S. Department of Defense, Eli Lilly and Company, Novo Nordisk, or any other trademark holder mentioned in this article.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Does TRICARE cover Mounjaro for type 2 diabetes?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. TRICARE covers Mounjaro for FDA-approved type 2 diabetes treatment across all plan types without prior authorization. Active-duty members pay $0 at MTF pharmacies. TRICARE Prime family members pay $13 to $34 per month. TRICARE Select beneficiaries pay 20% cost-sharing (approximately $220 per month) until reaching the annual catastrophic cap." } }, { "@type": "Question", "name": "Does TRICARE cover Mounjaro for weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Conditionally. TRICARE requires prior authorization for weight-loss use. Approval requires BMI 30 or above (or 27+ with comorbidities), documented failure of at least two prior weight-loss interventions, and comprehensive weight management plan. Approval rate is approximately 18%. Most denials cite availability of FDA-approved alternatives like Wegovy." } }, { "@type": "Question", "name": "How much does Mounjaro cost with TRICARE?", "acceptedAnswer": { "@type": "Answer", "text": "Cost depends on plan type and pharmacy. Active-duty members pay $0 at MTF pharmacies. TRICARE Prime family members pay $13 at MTF or $34 at retail. TRICARE Select beneficiaries pay 20% of negotiated rate (approximately $220 per month) until reaching catastrophic cap, after which all covered services are free." } }, { "@type": "Question", "name": "Does TRICARE cover compounded tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "No. TRICARE categorically excludes compounded medications when a commercially available version exists. Mounjaro is commercially available, so compounded tirzepatide receives zero coverage regardless of indication, cost, or access barriers. Beneficiaries who choose compounded tirzepatide pay entirely out of pocket." } }, { "@type": "Question", "name": "Can I use the Mounjaro Savings Card with TRICARE?", "acceptedAnswer": { "@type": "Answer", "text": "No. The Mounjaro Savings Card explicitly excludes government insurance beneficiaries, including TRICARE, Medicare, and Medicaid. Federal anti-kickback laws prohibit manufacturers from subsidizing copays for government insurance beneficiaries. TRICARE beneficiaries cannot use manufacturer coupons even if paying cash." } }, { "@type": "Question", "name": "What is the prior authorization process for Mounjaro weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "The provider submits a prior authorization request to Express Scripts with documentation of BMI, weight-related comorbidities, prior intervention failures, and comprehensive weight management plan. Review takes 14 to 21 business days. Approval rate is approximately 18% on first submission. Denials can be appealed through reconsideration and formal appeal processes." } }, { "@type": "Question", "name": "Does TRICARE For Life cover Mounjaro?", "acceptedAnswer": { "@type": "Answer", "text": "TRICARE For Life pays secondary to Medicare Part D. Coverage depends on the beneficiary's Part D plan formulary. If Part D covers Mounjaro, TRICARE For Life covers cost-sharing gaps. If Part D excludes Mounjaro, TRICARE For Life does not provide coverage. Beneficiaries must switch Part D plans or pay cash." } }, { "@type": "Question", "name": "How long does TRICARE prior authorization take?", "acceptedAnswer": { "@type": "Answer", "text": "Standard prior authorization review takes 14 to 21 business days from submission to decision. Urgent requests can be expedited to 72 hours if the provider documents medical urgency. Reconsideration requests take an additional 14 business days. Formal appeals take 45 business days." } }, { "@type": "Question", "name": "Can active-duty members fill Mounjaro at retail pharmacies?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, but only after attempting MTF pharmacy fill first. If the MTF pharmacy does not stock Mounjaro, the beneficiary must obtain DD Form 2161 (retail network authorization) from the MTF pharmacy chief. Processing takes 2 to 7 business days. Retail fills cost $13 per month for active duty." } }, { "@type": "Question", "name": "What happens if TRICARE denies my Mounjaro prior authorization?", "acceptedAnswer": { "@type": "Answer", "text": "You can file a reconsideration request within 30 days with additional documentation. If reconsideration is denied, you can file a formal appeal to the TRICARE regional contractor within 60 days. If the formal appeal is denied, you can appeal to TRICARE Management Activity within 90 days. Alternatively, you can pay cash for brand-name Mounjaro ($900-$1,100/month) or compounded tirzepatide ($299-$399/month)." } }, { "@type": "Question", "name": "Does TRICARE cover Wegovy instead of Mounjaro for weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, with prior authorization. Wegovy (semaglutide 2.4 mg) is FDA-approved for obesity and has a higher prior authorization approval rate (approximately 45%) than off-label Mounjaro. The coverage criteria are identical: BMI 30+ or 27+ with comorbidities, plus documented prior intervention failures. Many beneficiaries try Wegovy first because approval is more likely." } }, {